Novo Nordisk A/S (NVO)
39.07
+0.57
(+1.48%)
USD |
NYSE |
Mar 05, 16:00
39.12
+0.05
(+0.13%)
After-Hours: 20:00
Novo Nordisk Cash from Investing (Quarterly) : -6.527B for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Ascendis Pharma A/S | -3.872M |
| Evaxion AS | -- |
| Regeneron Pharmaceuticals, Inc. | 220.30M |
| Viking Therapeutics, Inc. | 75.61M |
| DBV Technologies SA | -0.2404M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.243B |
| Cash from Financing (Quarterly) | 4.428B |
| Free Cash Flow | 4.403B |
| Free Cash Flow Per Share (Quarterly) | -1.224 |
| Free Cash Flow to Equity (Quarterly) | -10.11B |
| Free Cash Flow to Firm (Quarterly) | -5.447B |
| Free Cash Flow Yield | 2.53% |